The concerns of rosuvastatin clinical efficacy and safety

Автор: Kukharchuk V.V., Malyshev P.P.

Журнал: Евразийский кардиологический журнал @eurasian-cardiology-journal

Рубрика: Оригинальные статьи

Статья в выпуске: 2, 2013 года.

Бесплатный доступ

In the article the authors consider some concerns of clinical efficacy and safety of rosuvastatin - the most powerful representative of the group of statins. The review contains the results of clinical trials, demonstrating its high lipid-lowering efficacy, impact on surrogate and primary endpoints in studies on primary and secondary prevention. They also discuss safety treatment concerns with this drug, and its possible side effects. The authors present data on the comparative efficacy and tolerability of generic form of rosuvastatin (Mertenil, Gedeon Richter) which had been received by Russian and foreign researchers, the evidence about the comparability of therapeutic efficacy and safety of the generic to the original form.

Еще

Atherosclerosis, rosuvastatin, statins, mertenil

Короткий адрес: https://sciup.org/14342739

IDR: 14342739

Статья научная